Table 3 Changes in eGFR before and after using dotinurad: stratified analysis regarding gender, age, CKD stage and primary disease
n | ΔeGFR-pre | ΔeGFR-post | p-value | |||
|---|---|---|---|---|---|---|
Mean | SD | Mean | SD | |||
All | 35 | -3.7 | 5.6 | 4.7 | 9.5 | < 0.001 |
Gender | ||||||
Male | 25 | -4.6 | 6 | 3.2 | 5.3 | 0.001 |
Female | 10 | -1.5 | 3.7 | 8.6 | 15.6 | 0.061 |
Age | ||||||
65 or higher | 23 | -4 | 3.1 | 4.6 | 10.8 | < 0.001 |
< 65 | 12 | -3.3 | 8.3 | 4.9 | 7.3 | 0.075 |
CKD stage at starting of treatment (mL/min/1.73 m2) | ||||||
G3 | 17 | -3.9 | 3.6 | 2.6 | 2.1 | < 0.001 |
G4 | 13 | -2.0 | 3.8 | 6.2 | 14.1 | 0.043 |
G5 | 5 | -7.7 | 11.8 | 8.0 | 10.8 | 0.195 |
Primary disease | ||||||
Gout kidney | 5 | -4.9 | 1.6 | 3.2 | 1.5 | 0.001 |
Diabetic kidney disease | 5 | -3.3 | 2.5 | 0.8 | 1.9 | 0.047 |
Nephrosclerosis | 8 | -2.1 | 2.6 | 2.8 | 1.9 | 0.016 |
Chronic glomerulonephritis | 17 | -4.3 | 7.6 | 7.2 | 13.3 | 0.010 |